Loading...
Market
How will competitors react to the success of the ARC-EX Stimulator by the end of 2026?
5
Resolution / Starting Odds
2 or more new competitors enter the market • 25%
1 new competitor enters the market • 25%
No new competitors, existing competitors enhance products • 25%
No significant market change • 25%
Market analysis reports, press releases from competing companies
Story
Onward Medical's ARC-EX Stimulator Shows Promising Results in Clinical Trial
May 20, 2024, 03:32 PM
A new non-invasive spinal cord stimulator developed by Onward Medical has shown promising results in aiding the recovery of people with spinal injuries. The device, known as ARC-EX, uses a 10 kilohertz current to numb the skin and provide stronger electrical stimulation. In a clinical trial, the stimulator improved hand and arm function in 72% of participants, including 43 individuals with tetraplegia. Approximately 18,000 people suffer from spinal cord injuries each year, and this extraordinary device could significantly enhance their rehabilitation process when paired with rehab. The results of the trial were published in Nature Medicine.
View original story
Similar markets
Increase in competing acquisitions • 33%
No significant changes • 34%
Reduction in investments • 33%
Launch similar products • 25%
No change in products • 25%
Increase marketing efforts • 25%
Lower prices of existing products • 25%
Competitors increase market efforts • 33%
Competitors form strategic alliances • 33%
No significant change in competitor strategies • 34%
Introduction of similar technologies • 25%
Partnerships or acquisitions to enhance capabilities • 25%
Increased investment in R&D • 25%
No significant response • 25%
No competitive drugs launched • 25%
1-2 competitive drugs launched • 25%
3-5 competitive drugs launched • 25%
More than 5 competitive drugs launched • 25%
No competitors respond • 25%
1-2 competitors respond • 25%
3-5 competitors respond • 25%
More than 5 competitors respond • 25%
No competitors • 33%
1-2 competitors • 33%
3 or more competitors • 33%
Increase in competitive services • 33%
Partnerships or acquisitions • 33%
No significant response • 33%
Gain significant market share • 33%
Moderate increase in market share • 33%
Minimal or no change in market share • 34%
No competitors • 25%
1 competitor • 25%
2 competitors • 25%
3 or more competitors • 25%
Increase in partnerships • 33%
Increased litigation against other firms • 33%
Boost in stock market presence • 34%
Significant increase in Promega's stock price • 33%
Moderate increase in Promega's stock price • 33%
No significant change in Promega's stock price • 34%